-

Tigerlily Foundation and Labcorp Collaborate to Increase Clinical Trial Diversity for Women of Color

BURLINGTON, N.C. & ALDIE, Va.--(BUSINESS WIRE)--Labcorp, a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions. Labcorp has signed Tigerlily’s #InclusionPledge for Black Women, joining other healthcare and life sciences companies in committing to eradicate barriers for women of color in accessing cancer care and research. Together, Tigerlily and Labcorp will work to end health disparities through the #InclusionPledge.

“Race, literacy, financial barriers, access, social, systemic and hereditary backgrounds should not be determinants of life and health equity. To continue to accelerate and make an impact as it relates to disparities and women of color, the #InclusionPledge is imperative. As an organization, Tigerlily Foundation was founded to address inequity—of age, of stage and of color. We have invested significantly in addressing disparities affecting women of color—to ensure that they are equal partners at every table and will continue to do so. We are honored to have Labcorp support the #InclusionPledge, as they are so closely associated with many initiatives directly impacting the future of patient care. We are looking forward to our ongoing relationship and activities to foster inclusion,” said Tigerlily Foundation CEO and Founder, Maimah Karmo.

The mission of the #InclusionPledge is to advocate and activate the inclusion of women of color across initiatives impacting overall health. The pledge provides a transparent and tangible framework across industry and healthcare stakeholders that identifies and tracks equity actions, and holds organizations accountable to specific, measurable outcomes that can lead to greater health equity for women of color. The #InclusionPledge focuses on moving stakeholders from talk to transformation and driving change and innovation.

This collaboration focuses on finding solutions to promote health equity amongst women of color and dismantle barriers that have made access to clinical trials challenging.

“Making healthcare accessible to all and encouraging a company culture that embraces diversity is a priority at Labcorp,” said Brenda Velasquez Wagner, chief diversity and inclusion officer at Labcorp. “By signing the #InclusionPledge, we continue to support diversity across all areas of healthcare, especially in clinical trials, where a diverse population of participants provides valuable and necessary insight into effective patient care. Labcorp is committed to inclusive clinical research and is driving innovative solutions to increase representation of racial and ethnic minorities in clinical trials. Labcorp is working to build trust across communities with various engagement activities, including the Tigerlily Community Listening Summit to gain insights from breast, ovarian and cervical cancer patients to incorporate into clinical trials and develop a best practices framework to make sites more inclusive.”

The #InclusionPledge is one of many actions led by Tigerlily to improve awareness, education, access, delivery and outcomes of treatments, and resources for women with breast cancer. To date, the Inclusion Pledge has more than twelve thousand individual signatures and more than 90 commitments from corporations and institutions.

To sign the #InclusionPledge for your organization visit: https://www.tigerlilyfoundation.org/inclusionpledgeforblackwomen

About Tigerlily Foundation

Tigerlily Foundation is a national breast cancer foundation providing education, awareness, advocacy and hands-on support to young women (ages 15-45) – before, during and after breast cancer. Tigerlily programs seek to educate and empower women of all backgrounds, including those at heightened risk, those facing health disparities, and those with less access to care. Tigerlily improves the quality of life and ends isolation among breast cancer survivors. Follow Tigerlily Foundation on LinkedIn and Twitter @Tigerlilycares.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Contacts

Labcorp Contacts:

Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com

Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

Tigerlily Foundation Contact:

info@tigerlilyfoundation.org

LABORATORY CORPORATION OF AMERICA HOLDINGS

NYSE:LH
Details
Headquarters: Burlington, NC
CEO: Adam Schechter
Employees: 75,000
Organization: PUB
Revenues: $16.1 billion (2021)
Net Income: $2.37 billion (2021)

Release Versions

Contacts

Labcorp Contacts:

Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com

Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

Tigerlily Foundation Contact:

info@tigerlilyfoundation.org

More News From LABORATORY CORPORATION OF AMERICA HOLDINGS

Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking

BOSTON--(BUSINESS WIRE)--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans. According to the National Institute on Aging (NIA), more than 1 million women trans...

Labcorp Announces 2022 Fourth Quarter and Full-Year Results

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance. “We finished the year strong, with accelerated revenue growth in Diagnostics, continued strong underlying fundamentals in Drug Development and margin expansion,” said Adam Schechter, chairman and CEO of Labcorp. “In 2022, we also advanced our strategy with the announcement of the spin of our Clinical...

Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial ma...
Back to Newsroom